SpringWorks Therapeutics Accounts Payable

SpringWorks Therapeutics (SWTX) currently reports a accounts payable of $15M as of March 2025. That compares with $7M in the prior-year period — up 112.9% year over year. Use the charts on this page to explore SpringWorks Therapeutics's accounts payable history and peer comparisons.

SpringWorks Therapeutics's accounts payable increased from $7M to $15M — a 112.9% year-over-year increase (period ending March 2025). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

SpringWorks Therapeutics reported $15M in accounts payable as of March 2025. That compares with $7M in the prior-year period — up 112.9% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current accounts payable of $15M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for SpringWorks Therapeutics, and consider following SWTX for alerts when major investors trade the stock.

SpringWorks Therapeutics is classified in the Healthcare sector. On accounts payable, it currently shows $15M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing SWTX with unrelated industries.